缬沙坦联合氨氯地平治疗中老年高血压并发蛋白尿128例

Combination of Valsartan and Amlodipine in the Treatment of 128 Cases of Middle-aged and Elderly Patients with Hypertension Complicated with Proteinuria

目的总结缬沙坦联合氨氯地平治疗中老年高血压并发蛋白尿的效果。方法2016年1月—2017年12月回顾性分析128例中老年高血压并发蛋白尿患者临床资料,所有患者在常规治疗基础上联用氨氯地平、缬沙坦,记录其用药前后SBP、DBP、24h尿蛋白定量变化情况及药物相关不良反应发生情况。结果128例中老年高血压并发蛋白尿患者治疗后SBP、DBP、24h尿蛋白定量均较治疗前显著下降(t=54.3904、37.3453、44.2154;P=0.0000、0.0000、0.0000);128例患者药物相关不良反应发生率为3.13%,发生药物相关不良反应后均未予以对症干预,停药后相应症状均好转或消失。结论缬沙坦联合氨氯地平治疗中老年高血压并发蛋白尿患者效果显著,同时能够有效保障临床用药安全性。

Objective To summarize the effects of valsartan combined with amlodipine in the treatment of hypertensive proteinuria in middle-aged and elderly patients. Methods The clinical data of 128 patients with hypertension complicated with proteinuria from January 2016 to December 2017 were retrospectively analyzed. All patients were treated with amlodipine and valsartan on the basis of routine treatment. The quantitative changes of SBP, DBP and 24 h urine protein, the occurrence of drug-related adverse reactions before and after treatment were recorded. Results SBP, DBP, and 24 h urine protein levels were significantly lower in 128 elderly patients with hypertension complicated with proteinuria than before treatment (t=54.390 4, 37.345 3, 44.215 4;P=0.000 0, 0.000 0, 0.000 0);128 patients with drugs incidence of related adverse reactions was 3.13%. No symptomatic intervention was observed after drug-related adverse reactions. The symptoms were all improved or disappeared after stopping the drug. Conclusion Valsartan combined with amlodipine is effective in the treatment of middle-aged and elderly patients with hypertension and proteinuria, and it can effectively guarantee the safety of clinical medication.